As of 2:05pm ET
| +0.0223 / +4.06%|
The 4 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 2.75, with a high estimate of 3.50 and a low estimate of 1.25. The median estimate represents a +381.19% increase from the last price of 0.57.
The current consensus among 4 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.